Showing papers for search query "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"

     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title FDA perspective on continuous manufacturing
     Author ['S Chatterjee']
     Venue IFPAC Annual Meeting, Baltimore, MD
     Year 2012
     Abstract assurance in real-time – Amenable to Real Time Release Testing approaches – Consistent quality Potential for reduced cost  continuous manufacturing • Continuous manufacturing consistent with FDA's Quality by Design (QbD) efforts – More modern manufacturing approach
     Url http://gmpua.com/Process/ContinuousManufacturing/ContinuousManufacturing.pdf


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Current FDA perspective for continuous manufacturing
     Author ['SL Lee']
     Venue 2nd International Symposium on Continuous …
     Year 2016
     Abstract Deputy Director (Acting) & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US FDA Center for Drug Evaluation and Research MIT-CMAC 2nd International Symposium on Continuous Manufacturing of Pharmaceuticals
     Url http://iscmp.mit.edu/sites/default/files/documents/ISCMP%202016%20-%20FDA%20MIT-CMAC%20for%20CM%202016%20Ver6.pdf


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title FDA approval of nonadjunctive use of continuous glucose monitors for insulin dosing: a potentially risky decision
     Author ['AR Shapiro']
     Venue Jama
     Year 2017
     Abstract Food and Drug Administration (FDA) approved labeling for use of the Dexcom G5 Mobile continuous glucose monitor (CGM) for making diabetes treatment decisions without a need for confirmation of the device's readings with fingerstick or laboratory testing (ie, nonadjunctively
     Url https://jamanetwork.com/journals/jama/article-abstract/2654258


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title The impact of continuous glucose monitoring on hospital point-of-care testing programs
     Author ['FL Kiechle']
     Venue Diabetes Technology & Therapeutics
     Year 2001
     Abstract analyzer approved for home use by the US Food and Drug Administration (FDA).9 This  usually performed by a nurse,10 and the point-of-care testing is administered  All laboratory methods, including fingerstick or continuous glucose measurements, are subject to preanalyt- ical
     Url https://www.liebertpub.com/doi/pdf/10.1089/15209150152811298


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
     Author ['F Dieterle', 'F Sistare', 'F Goodsaid', 'M Papaluca']
     Venue Nature …
     Year 2010
     Abstract A Nature Research Journal. Menu Nature Biotechnology Nature Biotechnology. Search E-alert Submit My Account Login. Perspective; Published: 10 May 2010. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
     Url https://www.nature.com/articles/nbt.1625?message-global=remove&page=7


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs
     Author ['EH Morrato', 'B Druss', 'DM Hartung']
     Venue Archives of general …
     Year 2010
     Abstract Geodon (ziprasidone): Dear Healthcare Practitioner letter, August 2004.http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts  Morrato EHNewcomer JWAllen RRValuck R Prevalence of baseline serum glucose and lipid testing in users of
     Url https://jamanetwork.com/journals/jamapsychiatry/article-abstract/210512


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Modernizing pharmaceutical manufacturing: from batch to continuous production
     Author ['SL Lee', "TF O'Connor", 'X Yang', 'CN Cruz']
     Venue Journal of …
     Year 2015
     Abstract Continuous manufacturing is strongly aligned with the FDA's support of the quality-by-design  The control strategy for a continuous process should be designed to control the quality of  2 control consists of pharmaceutical control with appropriate end-product testing and flexible
     Url https://link.springer.com/article/10.1007/s12247-015-9215-8


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Janssen working on other continuous processes post US FDA OK for Prezista
     Author ['G MacDonald']
     Venue inpharmatechnologist. com
     Year 2016
     Abstract In an accompanying blog post Lawrence Yu, deputy director of the FDA's office of pharmaceutical quality  Craig Stoltz, Janssen manufacturing and technical operations spokesman, told us “the benefits of Continuous Manufacturing include reduced testing-to-release time
     Url http://swedish.troudigital.com/wp-content/uploads/2016/01/Janssen-working-on-other-continuous-processes-post-US-FDA-OK-for-Prezista.pdf


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Present and future for continuous manufacturing: FDA perspective
     Author ['S Lee']
     Venue Proceedings of the 3rd FDA/PQRI Conference on …
     Year 2017
     Abstract Page 1. Present and Future for Continuous Manufacturing: FDA Perspective Sau (Larry) Lee, Ph.D. Deputy Director (Acting) & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US FDA Center for Drug Evaluation and Research
     Url http://pqri.org/wp-content/uploads/2017/02/1-Lee-PQRI-for-CM-2017.pdf


     Search term "Continuous"+"FDA"+"Software+Validation"+OR+"Software+Verification"+OR+"Testing"
     Title Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing
     Author ['LD Fisher']
     Venue Controlled clinical trials
     Year 1999
     Abstract We assume further that the true (unknown) magnitude of effect is the same in each study and that the standard deviation in a continuous end point (eg, change in blood pressure  The point is that a rigid approach to the usual FDA hypothesis testing paradigm violates
     Url https://www.sciencedirect.com/science/article/pii/S0197245698000543

